{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:40:57Z","timestamp":1769510457005,"version":"3.49.0"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>In the era of highly active antiretroviral therapy (HAART), standard\u2010dose chemotherapy for human immunodeficiency virus (HIV)\u2010associated diffuse large B\u2010cell lymphoma is becoming the standard of care. In contrast, the safety and efficacy of intensive regimens have not been established for Burkitt lymphoma (BL), a highly aggressive lymphoma for which moderate\u2010dose chemotherapy is substandard in the HIV\u2010negative population.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>To evaluate the feasibility of intensive chemotherapy in HIV\u2010associated BL, the authors retrospectively reviewed 14 HIV\u2010positive adults with BL treated at their center between 1988 and 2000. Eight patients were treated between 1996 and 2000 with cyclophosphamide, doxorubicin, high\u2010dose methotrexate\/ifosfamide, etoposide, and high\u2010dose cytarabine (CODOX\u2010M\/IVAC), one of the currently preferred intensive\u2010dose chemotherapy regimens for BL. Six received other chemotherapy. Outcomes were compared with those of 24 HIV\u2010negative adult patients with BL who had similar patient characteristics and were treated concomitantly (13 with CODOX\u2010M\/IVAC; 11 with other regimens).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of the 14 HIV\u2010positive patients, 63% had a complete response after CODOX\u2010M\/IVAC treatment, compared with 67% of patients receiving other chemotherapy. The 2\u2010year event\u2010free survival (EFS) rates were 60% and 60% after CODOX\u2010M\/IVAC or other regimens, respectively. Similar outcomes were seen despite the fact that 88% of CODOX\u2010M\/IVAC\u2010treated HIV\u2010positive patients had Stage IV disease, compared with one\u2010third of HIV\u2010positive patients treated with other chemotherapy. HIV status did not adversely affect long\u2010term EFS independent of the treatment regimen (<jats:italic>P<\/jats:italic> = 0.88). When EFS was evaluated according to chemotherapy regimen independent of HIV status, CODOX\u2010M\/IVAC was found to be associated with improved EFS (<jats:italic>P<\/jats:italic> = 0.05) in all patients, and particularly those at high risk. HIV\u2010positive patients treated with CODOX\u2010M\/IVAC tolerated chemotherapy well with similar rates of myelosuppression and infectious complications as HIV\u2010negative patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The current nonrandomized retrospective study suggested that intensive chemotherapy with CODOX\u2010M\/IVAC is feasible and well tolerated in HIV\u2010positive adults with BL. In the post\u2010HAART era, intensive chemotherapy such as CODOX\u2010M\/IVAC may be appropriate in all adult patients with BL, and especially those with poor prognostic factors, regardless of HIV status. Cancer 2003;98:1196\u2013205. \u00a9 2003 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.11628<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11628","type":"journal-article","created":{"date-parts":[[2003,9,10]],"date-time":"2003-09-10T09:35:52Z","timestamp":1063186552000},"page":"1196-1205","source":"Crossref","is-referenced-by-count":126,"title":["Intensive chemotherapy with cyclophosphamide, doxorubicin, high\u2010dose methotrexate\/ifosfamide, etoposide, and high\u2010dose cytarabine (CODOX\u2010M\/IVAC) for human immunodeficiency virus\u2013associated Burkitt lymphoma"],"prefix":"10.1002","volume":"98","author":[{"given":"Eunice S.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Teruya\u2010Feldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Portlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hedrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariela","family":"Noy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,8]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880035"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1967)20:5<756::AID-CNCR2820200530>3.0.CO;2-P"},{"key":"e_1_2_5_6_2","first-page":"389","article-title":"Burkitt's lymphoma in adults: a retrospective study of 46 cases","volume":"34","author":"Ostronoff M","year":"1992","journal-title":"Nouv Rev Fr Hematol."},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0753-3322(97)86004-0"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706053362304"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03470010088036"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.925"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf253"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/103.5.561"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.1.8.8"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92513-2"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<766::AID-CNCR21>3.0.CO;2-V"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3788"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.9.1322"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_20_2","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel N","year":"1966","journal-title":"Cancer Chemother Rep."},{"key":"e_1_2_5_21_2","first-page":"345","volume-title":"Fundamentals of biostatistics","author":"Rosner B","year":"1994"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_5_23_2","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res."},{"key":"e_1_2_5_24_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V49.3.325.325","article-title":"Combination chemotherapy (\u201cCHOP\u2010Bleo\u201d) in advanced (non\u2010Hodgkin) malignant lymphoma","volume":"49","author":"Rodriguez V","year":"1977","journal-title":"Blood."},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)80013-C"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-6-757"},{"key":"e_1_2_5_27_2","first-page":"249a","article-title":"An economic analysis of the NHL\u201015 protocol for diffuse aggressive lymphomas: the potential for substantially reducing cost by improving outcomes","volume":"90","author":"O'Brien JP","year":"1997","journal-title":"Am Soc Hematol."},{"key":"e_1_2_5_28_2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1200\/JCO.1991.9.6.941","article-title":"Effective treatment of small\u2010noncleaved\u2010cell lymphoma with high\u2010intensity, brief\u2010duration chemotherapy","volume":"9","author":"McMaster ML","year":"1991","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.6.847"},{"key":"e_1_2_5_30_2","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.1994.12.10.2153","article-title":"Diffuse small noncleaved\u2010cell, non\u2010Burkitt's lymphoma in adults: a high\u2010grade lymphoma responsive to ProMACE\u2010based combination chemotherapy","volume":"12","author":"Longo DL","year":"1994","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197707142970202"},{"key":"e_1_2_5_32_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1200\/JCO.1990.8.4.615","article-title":"Small noncleaved cell lymphoma in adults: superior results for Stages I\u2010III disease","volume":"8","author":"Lopez TM","year":"1990","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2171"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02656.x"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90259-R"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053542"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.6.1099"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.22.1823"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10365"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11628","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:36:22Z","timestamp":1760258182000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,9,15]]}},"alternative-id":["10.1002\/cncr.11628"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11628","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8]]}}}